Document is current

Article History

Received: 4 February 2023

Accepted: 18 September 2023

First Online: 25 September 2023

Declarations

:

: The B-DASH study is being conducted in compliance with the principles of the Declaration of Helsinki, and it was approved by the central review board of Shizuoka Cancer Center. Written informed consent will be obtained from participants.

: Not applicable.

: KW, HK, HA, MT, TY, KN, and NY have received personal fees and / or grants from Takeda Pharmaceutical Company Limited. Disclosures other than Takeda Pharmaceutical Company Limited are follows; KW reports grants and personal fees from Chugai Pharmaceutical Co.,Ltd, Astrazeneca, Novartis, Abbvie, AMGEN, MSD, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K, Ono Pharmaceutical, Janssen Pharmaceutical K.K., and Daiichi Sankyo. HK reports grants and personal fees from AstraZeneca, Chugai Pharmaceutical Co, Ltd., Eli Lilly K.K, LOXO Oncology, Novartis Pharma K.K., Ono Pharmaceutical Co, Ltd., AMGEN, MSD, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merk, Pfizer, and Taiho Pharma. YS reports personal fees from AstraZeneca, MSD, Novartis, Chugai Pharmaceutical, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, Nippon Kayaku, Bristol Myers Squibb, Eli Lilly, and Kyowa Kirin. AN reports personal fees from AstraZeneca, Thermo Fisher Scientific, Chugai Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Inc., NIPPON KAYAKU, Merck, and Novartis. HA reports grants and personal fees from Amgen Inc, Chugai Pharmaceutical Co. Ltd., MSD K.K., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb, Eli Lilly Japan K.K., Nippon Kayaku. Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Taiho Pharmaceutical Co. Ltd. MT reports personal fees from Eli Lilly Japan Co Ltd, Ono Pharmaceutical Co Ltd, Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co Ltd, AstraZeneca KK, MSD KK, and Novartis pharmaceuticals K.K. SM reports honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Boehringer-Ingelheim Japan. TY reports grants and personal fees from MSD, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Boehringer Ingelheim Japan Inc., AstraZeneca K.K., Eli Lilly Japan K.K., Pfizer Japan Inc, Ono Pharmaceutical Co. Ltd., and Nippon Kayaku Co., Ltd. KM reports no competing-interest. KN reports grants, personal fees from AstraZeneca K.K., MSD K.K., Ono Pharmaceutical Co.,Ltd., Nippon Boehringer Ingelheim Co.,Ltd., Novartis Pharma K.K., Pfizer Japan Inc., Bristol Myers Squibb Company, Eli Lilly Japan K.K., Chugai Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Merck Biopharma Co., Ltd., PAREXEL International Corp., PRA HEALTHSCIENCES, EPS Corporation., Kissei Pharmaceutical Co., Ltd., EPS International Co.,Ltd,, Taiho Pharmaceutical Co.,Ltd., PPD-SNBL K.K, SymBio Pharmaceuticals Limited., IQVIA Services JAPAN K.K., SYNEOS HEALTH CLINICAL K.K., Nippon Kayaku Co.,Ltd., EP-CRSU Co., Ltd., Mebix, Inc., Janssen Pharmaceutical K.K., AbbVie Inc., Bayer Yakuhin, Ltd, Eisai Co., Ltd., Mochida Pharmaceutical Co., Ltd., Covance Japan Inc., Japan Clinical Research Operations, GlaxoSmithKline K.K., Sanofi K.K., Sysmex Corporation, Medical Reserch Support, Otsuka Pharmaceutical Co., Ltd., SRL, Inc., Pfizer R&D Japan G.K., Amgen Inc., KYORIN Pharmaceutical Co., Ltd., CMIC ShiftZero K.K., Life Technologies Japan Ltd., Neo Communication, Roche Diagnostics K.K., Kyowa Kirin Co., Ltd., 3H Clinical Trial Inc., Care Net, Inc., Medical Review Co., Ltd., Medical Mobile Communications co., Ltd, YODOSHA CO., LTD., Nikkei Business Publications, Inc., Japan Clinical Research Operations, and CMIC Co., Ltd. NY reports grants and personal fees from Boehringer-Ingelheim, Taiho, Chugai, Shionogi, Eli Lilly Japan, Daiichi-Sankyo, Tumura, Nippon Kayaku, Asahikasei-pharma, AstraZeneca, Janssen, Sanofi, AMGEN, Novartis, Astellas, MSD, Esai, Bristol Myers Squibb, Abbvie, Tosoh, Ono, Otsuka, Guardant Health Japan, Kyowa-Kirin, Kyorin, GlaxoSmithKline, Sanofi, Daiichi-Sankyo, Pfizer, and Miyarisan, Merck.